Cisplatin has been the most successful anticancer drug used to treat many types of cancer; however, it has an uncertain effect on PCa and moderately decreases prostate-specific antigen (PSA), mainly due to its cellular toxicity and acquired resistance [8,9,10,11,12]. Here, KLK3 is linked to posterior cortical atrophy.